Predicting Response to Immunotherapy: Assessing the Tumor Micro-Environment to Achieve Better Predictive Value than PD-L1 and TMB
America/Los_Angeles (PT) -7
PREDICTING RESPONSE TO IMMUNOTHERAPY: ASSESSING THE TUMOR MICRO-ENVIRONMENT TO ACHIEVE BETTER PREDICTIVE VALUE THAN PD-L1 AND TMB
Up to 750,000 patients are eligible for immunotherapy each year, yet more than half of these patients won’t respond. There continues to be a critical unmet need for a predictive biomarker than can identify responders and non-responders at diagnosis. DetermaIO is a novel test that measures expression of 27 genes from the tumor microenvironment and uses a proprietary algorithm to predict response to immunotherapies. In this webinar, we will present results from two studies showing the association of DetermaIO with response to checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). Both studies suggest that DetermaIO outperformed PD-L1 and/or TMB in predicting immunotherapy response. The studies were led by multiple leading academic institutions, including the University of Texas MD Anderson Cancer Center, Yale University, the Baylor College of Medicine, and the University of Tennessee Health Science Center.
Previous registration necessary?
Simultaneous translation ?
Will it be recorded?
Naoto Ueno, Douglas Ross